

HR 2244

Patient Experience in Research Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 28, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 5, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/2244>

Sponsor

Name: Rep. Lance, Leonard [R-NJ-7]

Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (3 total)

| Cosponsor | Party / State | Role | Date Joined |
|---------------------------------|---------------|------|--------------|
| Rep. DeGette, Diana [D-CO-1] | D · CO | | Apr 28, 2017 |
| Rep. Clarke, Yvette D. [D-NY-9] | D · NY | | May 22, 2017 |
| Rep. Eshoo, Anna G. [D-CA-18] | D · CA | | May 22, 2017 |

Committee Activity

| Committee | Chamber | Activity | Date |
|-------------------------------|---------|-------------|-------------|
| Energy and Commerce Committee | House | Referred to | May 5, 2017 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 28, 2017)

Patient Experience in Research Act of 2017

This bill requires the Food and Drug Administration to carry out a pilot project under which sponsors of new drugs or biological products agree to evaluate: (1) the distress experienced by patients in clinical trials for medications intended to treat a serious condition, and (2) the effects of providing support to distressed patients on the outcome of a clinical trial. The user fee is waived for new drug applications that include data from such an evaluation.

Actions Timeline

- **May 5, 2017:** Referred to the Subcommittee on Health.
- **Apr 28, 2017:** Introduced in House
- **Apr 28, 2017:** Referred to the House Committee on Energy and Commerce.